Modulation of Growth and Differential in Breast Cancer by Soy Isoflavones
Abstract
Our studies investigate the in vivo effects of soy isoflavones on human breast tissues obtained from lumpectomy/mastectomy specimens. We investigate the effect of increased tissue concentration of isoflavones for a period of three weeks on breast cell proliferation, differentiation and cell cycle regulatory proteins. Patients with ductal carcinoma in situ (DCISS) or invasive breast cancer are randomly assigned to take 100 mg soy isoflavone (Novasoy(TM), Archer Daniels Midland Company, Decatur, Illinois) or placebo daily for three weeks prior to surgery. Plasma isoflavone levels are measured at baseline and after three weeks in both groups. Tissue isoflavone levels are measured on samples from benign breast tissues in both groups. Biomarker studies are performed on surgical specimens by immunohistochemistry and Western blot. These studies will enable us to determine if a short duration of exposure to increased tissue levels of isoflavones will modulate biomarkers of cell differentiation (Cx43), adhesion (E-cadherin), proliferation (MIB-1), and cell growth and apoptosis (bcl-2, bax, p53, p21, Rb, EGF-R, cyclin Dl, CDK5, CDK6) in benign, pre-malignant and malignant areas of breast epithelial tissues. Biomarker studies on the patients randomized on this study will be completed in early 2003.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2000
- Accession Number
- ADA389952
Entities
People
- Omer Kucuk
Organizations
- Wayne State University